FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels

FDA approves Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children ages 2 and older in combination with steroid hormones. It is the first approved treatment for children with these rare vasculitis diseases.

Source: FDA Center for Drug Evaluation and Research - What's New - March 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news